Program
alpha-tocotrienol quinone
Also written as “Vatiquinone”, “EPI-743” and “EPI-743 400 mg”.
Its studies are mostly in Friedreich Ataxia · Leigh Disease · Mitochondrial Diseases · Autistic Disorder · VLCAD deficiency, led by PTC Therapeutics.
Furthest: phase 3, since May 4, 202013 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| PTC Therapeutics | 132 open or running | phase 3since May 4, 2020 | Nov 1, 2012 | Dec 31, 2027phase 3 · NCT05515536 |
Also a collaborator on its studies: axio-research-llc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 1, 2012First studies: 2 phase 2 studiesFirst studyNCT01721733, NCT01728064
- Mar 25, 2013Phase 2 study in Rett SyndromeNCT01822249 · 24 enrolled · Italy
- Apr 2, 2014Phase 2 study in VLCAD deficiencyNCT02104336 · 2 enrolled · United States
- Aug 11, 20143 phase 2 studiesNCT02257983, NCT02352896, NCT02226458
- May 4, 2020Phase 3 study in Mitochondrial DiseasesNCT04378075 · 68 enrolled · United States, Canada, France and more
- Sep 30, 2020Phase 3 study in Friedreich AtaxiaNCT04577352 · 146 enrolled · United States, Australia, Brazil and more
- Jan 19, 2022Phase 3 study in Leigh DiseaseNCT05218655 · 101 enrolled · United States, France, Italy and more
- Aug 1, 2022Phase 2 study in Friedreich AtaxiaNCT05485987 · 5 enrolled · United States
- Aug 23, 2022Phase 3 study in Friedreich AtaxiaNCT05515536 · 130 enrolled · United States, Australia, Brazil and more
- Jun 26, 2026Phase 3 study in Friedreich AtaxiaNCT07681713 · 120 planned · United States, Belgium, Brazil and more
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Friedreich AtaxiaNCT05515536
- Mar 15, 2029Primary completion: phase 3 study in Friedreich AtaxiaNCT07681713
TargetBeta
NQO1 →read by rule
“Quinone reductase 1 modulator”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07681713Friedreich Ataxia · United States, Belgium, Brazil and more | 3 | Not yet recruiting | Mar 15, 2029 | 120 |
| NCT05515536Friedreich Ataxia · United States, Australia, Brazil and more | 3 | Active, not recruiting | Dec 31, 2027 | 130 |
| NCT05485987Friedreich Ataxia · United States | 2 | Completed | Aug 29, 2024 | 5 |
| NCT05218655Leigh Disease · United States, France, Italy and more | 3 | Completed | Apr 15, 2025 | 101 |
| NCT04577352Friedreich Ataxia · United States, Australia, Brazil and more | 3 | Completed | Apr 4, 2023 | 146 |
| NCT04378075Mitochondrial Diseases · United States, Canada, France and more | 3 | Terminated | Mar 18, 2023 | 68 |
| NCT02352896Leigh Disease · United States | 2 | Completed | Oct 30, 2023 | 30 |
| NCT02226458Autism Spectrum Disorder | 2 | Withdrawn | Nov 30, 2015 | 0 |
| NCT02257983Hearing Loss, Noise-Induced · United States | 2 | Completed | Nov 30, 2015 | 77 |
| NCT02104336VLCAD deficiency · United States | 2 | Terminated | Nov 30, 2015 | 2 |
| NCT01822249Rett Syndrome · Italy | 2 | Completed | Dec 2013 | 24 |
| NCT01728064Friedreich Ataxia · United States | 2 | Completed | Oct 31, 2015 | 60 |
| NCT01721733Leigh Disease · United States | 2 | Completed | Feb 28, 2015 | 35 |
How it is read
Names in the registry
- “Vatiquinone”, 6 entries
- “EPI-743”, 5 entries
- “EPI-743 400 mg”, 1 entry
- “EPI-743 200 mg”, 1 entry
- “EPI-743 15 mg/kg”, 1 entry
Conditions, from the studies’ own filings
- Friedreich Ataxia, 5 studies
- Leigh Disease, 3 studies
- Mitochondrial Diseases, 1 study
- Autistic Disorder, 1 study
- VLCAD deficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.